Clinical Trial: Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720310) titled 'Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus' on July 13.

Brief Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease. In the treatment of SLE today, glucocorticosteroid hormones, cytostatics (azathioprine, cyclophosphamide, mycophenolate mofetil, hydroxychloroquine, etc.), and biological therapy (rituximab, belimumab) are widely used. However, this therapy has limitations: firstly, it does not always control the autoimmune pro...